Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ

Koichi Takayama, Hikaru Ueno, Yoichi Nakanishi, Taiji Sakamoto, Koji Inoue, Kiyoshi Shimizu, Hideya Oohashi, Nobuyuki Hara

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Antiangiogenic therapy shows promise as a strategy for cancer treatment. We constructed an adenovirus (AdVEGF-ExR) expressing the entire extracellular domain of the human vascular endothelial growth factor (VEGF) receptor (flt- I) fused to the Fc portion of human IgG. The soluble receptor secreted from AdVEGF-ExR-infected cells bound to VEGF and inhibited VEGF-induced DNA synthesis in endothelial cells. When human lung cancer cell line H157, which produces not only VEGF but also fibroblast growth factor 2 and interleukin 8 at substantial levels, was infected with AdVEGF-ExR, cell growth in vitro was not affected. However, when H157 cells infected with AdVEGF-ExR were injected s.c. into nude mice, tumor formation stopped on the 10th day after reaching a certain size (about 100 mm3), and tumor size declined gradually thereafter. When AdVEGF-ExR was injected into skeletal muscle and uninfected H157 cells were injected s.c., the soluble receptor was detectable in the circulating blood for 3 weeks, tumor growth ceased after 10 days, and tumor size declined thereafter. Histological examination revealed that intratumor angiogenesis was markedly suppressed, and apoptosis was enhanced. Using the same experimental protocol, a significant suppression of tumor growth was also seen in four of five other lung cancer cell lines, some of which secreted VEGF at nominal levels, at least under normoxic conditions in vitro. Our results demonstrate that adenovirus-mediated expression of a soluble VEGF receptor in a remote organ could inhibit tumor angiogenesis and enhance apoptosis and thereby suppress tumor growth in vivo. Adenovirus-mediated overexpression of a soluble VEGF receptor in a remote organ may have the potential to be a feasible and effective strategy for cancer treatment.

Original languageEnglish
Pages (from-to)2169-2177
Number of pages9
JournalCancer Research
Volume60
Issue number8
Publication statusPublished - Apr 15 2000

Fingerprint

Vascular Endothelial Growth Factor Receptor
Growth
Genes
Neoplasms
Vascular Endothelial Growth Factor A
Adenoviridae
Lung Neoplasms
Fibroblast Growth Factor 8
Apoptosis
Cell Line
Fibroblast Growth Factor 2
Interleukin-8
Nude Mice
Skeletal Muscle
Endothelial Cells
Immunoglobulin G
DNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takayama, K., Ueno, H., Nakanishi, Y., Sakamoto, T., Inoue, K., Shimizu, K., ... Hara, N. (2000). Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Research, 60(8), 2169-2177.

Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. / Takayama, Koichi; Ueno, Hikaru; Nakanishi, Yoichi; Sakamoto, Taiji; Inoue, Koji; Shimizu, Kiyoshi; Oohashi, Hideya; Hara, Nobuyuki.

In: Cancer Research, Vol. 60, No. 8, 15.04.2000, p. 2169-2177.

Research output: Contribution to journalArticle

Takayama, K, Ueno, H, Nakanishi, Y, Sakamoto, T, Inoue, K, Shimizu, K, Oohashi, H & Hara, N 2000, 'Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ', Cancer Research, vol. 60, no. 8, pp. 2169-2177.
Takayama, Koichi ; Ueno, Hikaru ; Nakanishi, Yoichi ; Sakamoto, Taiji ; Inoue, Koji ; Shimizu, Kiyoshi ; Oohashi, Hideya ; Hara, Nobuyuki. / Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. In: Cancer Research. 2000 ; Vol. 60, No. 8. pp. 2169-2177.
@article{434cf62bf0904d80bc64ff0d0e1fdff1,
title = "Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ",
abstract = "Antiangiogenic therapy shows promise as a strategy for cancer treatment. We constructed an adenovirus (AdVEGF-ExR) expressing the entire extracellular domain of the human vascular endothelial growth factor (VEGF) receptor (flt- I) fused to the Fc portion of human IgG. The soluble receptor secreted from AdVEGF-ExR-infected cells bound to VEGF and inhibited VEGF-induced DNA synthesis in endothelial cells. When human lung cancer cell line H157, which produces not only VEGF but also fibroblast growth factor 2 and interleukin 8 at substantial levels, was infected with AdVEGF-ExR, cell growth in vitro was not affected. However, when H157 cells infected with AdVEGF-ExR were injected s.c. into nude mice, tumor formation stopped on the 10th day after reaching a certain size (about 100 mm3), and tumor size declined gradually thereafter. When AdVEGF-ExR was injected into skeletal muscle and uninfected H157 cells were injected s.c., the soluble receptor was detectable in the circulating blood for 3 weeks, tumor growth ceased after 10 days, and tumor size declined thereafter. Histological examination revealed that intratumor angiogenesis was markedly suppressed, and apoptosis was enhanced. Using the same experimental protocol, a significant suppression of tumor growth was also seen in four of five other lung cancer cell lines, some of which secreted VEGF at nominal levels, at least under normoxic conditions in vitro. Our results demonstrate that adenovirus-mediated expression of a soluble VEGF receptor in a remote organ could inhibit tumor angiogenesis and enhance apoptosis and thereby suppress tumor growth in vivo. Adenovirus-mediated overexpression of a soluble VEGF receptor in a remote organ may have the potential to be a feasible and effective strategy for cancer treatment.",
author = "Koichi Takayama and Hikaru Ueno and Yoichi Nakanishi and Taiji Sakamoto and Koji Inoue and Kiyoshi Shimizu and Hideya Oohashi and Nobuyuki Hara",
year = "2000",
month = "4",
day = "15",
language = "English",
volume = "60",
pages = "2169--2177",
journal = "Cancer Research",
issn = "0008-5472",
number = "8",

}

TY - JOUR

T1 - Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ

AU - Takayama, Koichi

AU - Ueno, Hikaru

AU - Nakanishi, Yoichi

AU - Sakamoto, Taiji

AU - Inoue, Koji

AU - Shimizu, Kiyoshi

AU - Oohashi, Hideya

AU - Hara, Nobuyuki

PY - 2000/4/15

Y1 - 2000/4/15

N2 - Antiangiogenic therapy shows promise as a strategy for cancer treatment. We constructed an adenovirus (AdVEGF-ExR) expressing the entire extracellular domain of the human vascular endothelial growth factor (VEGF) receptor (flt- I) fused to the Fc portion of human IgG. The soluble receptor secreted from AdVEGF-ExR-infected cells bound to VEGF and inhibited VEGF-induced DNA synthesis in endothelial cells. When human lung cancer cell line H157, which produces not only VEGF but also fibroblast growth factor 2 and interleukin 8 at substantial levels, was infected with AdVEGF-ExR, cell growth in vitro was not affected. However, when H157 cells infected with AdVEGF-ExR were injected s.c. into nude mice, tumor formation stopped on the 10th day after reaching a certain size (about 100 mm3), and tumor size declined gradually thereafter. When AdVEGF-ExR was injected into skeletal muscle and uninfected H157 cells were injected s.c., the soluble receptor was detectable in the circulating blood for 3 weeks, tumor growth ceased after 10 days, and tumor size declined thereafter. Histological examination revealed that intratumor angiogenesis was markedly suppressed, and apoptosis was enhanced. Using the same experimental protocol, a significant suppression of tumor growth was also seen in four of five other lung cancer cell lines, some of which secreted VEGF at nominal levels, at least under normoxic conditions in vitro. Our results demonstrate that adenovirus-mediated expression of a soluble VEGF receptor in a remote organ could inhibit tumor angiogenesis and enhance apoptosis and thereby suppress tumor growth in vivo. Adenovirus-mediated overexpression of a soluble VEGF receptor in a remote organ may have the potential to be a feasible and effective strategy for cancer treatment.

AB - Antiangiogenic therapy shows promise as a strategy for cancer treatment. We constructed an adenovirus (AdVEGF-ExR) expressing the entire extracellular domain of the human vascular endothelial growth factor (VEGF) receptor (flt- I) fused to the Fc portion of human IgG. The soluble receptor secreted from AdVEGF-ExR-infected cells bound to VEGF and inhibited VEGF-induced DNA synthesis in endothelial cells. When human lung cancer cell line H157, which produces not only VEGF but also fibroblast growth factor 2 and interleukin 8 at substantial levels, was infected with AdVEGF-ExR, cell growth in vitro was not affected. However, when H157 cells infected with AdVEGF-ExR were injected s.c. into nude mice, tumor formation stopped on the 10th day after reaching a certain size (about 100 mm3), and tumor size declined gradually thereafter. When AdVEGF-ExR was injected into skeletal muscle and uninfected H157 cells were injected s.c., the soluble receptor was detectable in the circulating blood for 3 weeks, tumor growth ceased after 10 days, and tumor size declined thereafter. Histological examination revealed that intratumor angiogenesis was markedly suppressed, and apoptosis was enhanced. Using the same experimental protocol, a significant suppression of tumor growth was also seen in four of five other lung cancer cell lines, some of which secreted VEGF at nominal levels, at least under normoxic conditions in vitro. Our results demonstrate that adenovirus-mediated expression of a soluble VEGF receptor in a remote organ could inhibit tumor angiogenesis and enhance apoptosis and thereby suppress tumor growth in vivo. Adenovirus-mediated overexpression of a soluble VEGF receptor in a remote organ may have the potential to be a feasible and effective strategy for cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=0034655246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034655246&partnerID=8YFLogxK

M3 - Article

C2 - 10786681

AN - SCOPUS:0034655246

VL - 60

SP - 2169

EP - 2177

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -